• English
  • Korean
  • Chinese
市場調査レポート - 225405

世界の関節炎処方薬市場

The World Market for Prescription Arthritis Treatments (NSAIDs, DMARDs, BRMs and Immunosuppressants)

発行 Kalorama Information
出版日 ページ情報 英文 150 Pages
価格
世界の関節炎処方薬市場 The World Market for Prescription Arthritis Treatments (NSAIDs, DMARDs, BRMs and Immunosuppressants)
出版日: 2011年11月01日 ページ情報: 英文 150 Pages
概要

関節炎は世界でもっとも罹患率の高い疾患のひとつであり、完全には解明されていない多くの原因を持った複雑な筋骨格系の疾患群です。なかでも自己免疫性疾患であるリウマチ性関節炎がもっとも深刻です。現在では、さまざまな治療薬による効果的な治療が可能となっており、特に新たに開発されてた疾患修飾性治療薬が深刻な症状に高い効果を上げています。さらに併用療法の成長も顕著であり、疾患管理に高い効果をもたらしています。

当レポートでは、世界の関節炎処方薬市場の現状と見通しについて調査分析し、NSAID(非ステロイド系抗炎症性薬物)、DMARD(疾患修飾性抗リウマチ薬)、BRM(生体応答調節剤)および免疫抑制剤の区分における製品概要、市場予測(〜2016年)、地域動向、競合環境、関節炎処方薬市場への各種影響因子の分析、R&D動向、主要企業のプロファイルなどをまとめ、概略下記の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 イントロダクション

  • 概要
  • 局所的関節機能障害
  • 変形性関節症
  • 感染性関節炎
  • リウマチ性関節炎
  • 強直性脊椎炎
  • 乾癬性関節炎
  • 腸炎性関節炎
  • 成人発症スチル病
  • 若年性リウマチ性関節炎
  • スチル病
  • 多関節発症型
  • 世界の人口動態

第3章 世界の非ステロイド系抗炎症性薬物市場

  • 製品概要
  • 市場予測・成長率
  • 地域別市場
    • 米国
    • 欧州
    • 日本
    • その他の地域
  • 競合環境

第4章 世界の疾患修飾性抗リウマチ薬市場

  • 製品概要
  • 市場予測・成長率
  • 地域別市場
    • 米国
    • 欧州
    • 日本
    • その他の地域
  • 競合環境

第5章 世界の生体応答調節剤(BRM)・免疫抑制剤市場

  • 概要
  • T腫瘍壊死因子
  • グルココルチコイド
  • アザチオプリン(Azasan-Salix)
  • アダリムマブ(Humira-Abbott)
  • アナキンラ(Kineret-Amgen)
  • バシリキシマブ (Simulect-Novartis)
  • ダクリズマブ (Zenapax-Roche)
  • エタネルセプト(Enbrel-Amgen)
  • インフリキシマブ(Remicade-Janssen Biotech)
  • リツキサン(Rituxan-Biogen Idec)
  • アバタセプト (Orencia-Bristol-Myers Squibb)
  • 市場予測・成長率
  • 地域別市場
    • 米国
    • 欧州
    • 日本
    • その他の地域
  • 競合環境

第6章 世界の関節炎治療市場:サマリー・競合分析

  • 市場概要
  • 製品市場・サマリー
  • 製品市場分析:地域別
  • 世界の関節炎治療製品:競合分析

第7章 関節炎治療のR&D

  • 概要
  • Duexis
  • Gel-One
  • ACZ
  • Apremilast
  • Fostamatinib
  • Lodotra
  • Stelara
  • Tofacitinib

第8章 関節炎治療の課題と動向

  • 概要
  • 米国経済の影響
  • 世界経済の影響
  • 肥満症と関節炎
  • 保険・償還関連の動向
  • 抗TNF(腫瘍壊死因子)支配の脅威
  • ADAM遺伝子の発見
  • ドイツの新たな価格構造

第9章 総論

第10章 企業プロファイル

図表

目次

Abstract

Arthritis is one of the most common human ailments worldwide. Arthritis is a complex family of musculoskeletal disorders with many causes that are not fully understood. The most crippling of the arthritis family is rheumatoid arthritis, which is an autoimmune disease. Successful treatment of arthritis has resulted from a growing array of therapies available to physicians.

While these pharmaceutical products are still used regularly, new disease-modifying therapies have produced the most impressive results in treating more severe types of arthritis. Additionally, combination therapies continue to grow in preference and offer exciting results in disease management. This Kalorama Information report, The World Market for Prescription Arthritis Treatments, details the market for these treatments. The report provides market sizes and forecasts for the following categories of treatments:

  • Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • Disease Modifying Anti-Rheumatic Drugs (DMARDs)
  • Biologic Response Modifiers (BRMs) and Immunosuppressants

For each category, the report breaks down the regional market (US, Europe, Japan, Rest of World), lists major products, and provides market share among major competitors.

There are several issues and trends that are shaping this market. Some of the topics, discussed in this report include:

  • US Economic Impact of Arthritis
  • World Economic Impact of Arthritis
  • Obesity and Arthritis
  • Trends in Insurance and Reimbursement
  • Threat to Anti-TNF Dominance
  • ADAM-12 Gene Discovery
  • New Pricing Structure in Germany

The information and analysis presented in this report are based on extensive interviews with senior management of top companies in the worldwide arthritis treatment market. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 20 industry executives and product managers to validate and obtain expert opinion on current and future trends in the worldwide prescription arthritis treatment market. Interviews were also used to confirm and/or adjust market size estimates, as well as in formulating market projections.

The following companies are profiled in the report:

  • Abbott Laboratories
  • Amgen, Inc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Galapagos NV
  • Genentech, Inc.
  • Horizon Pharma
  • Janssen Biotech, Inc
  • Novartis International AG
  • Pfizer, Inc.
  • Roche
  • Regeneron
  • UCB

All market data pertains to the worldwide market at the manufacturers' level. Data are expressed in current U.S. dollars. A geographic breakdown is also included for US, Europe, Japan and Rest of World total market and in each drug type segment. The base year for data was 2011. Historical data are provided for each of the years 2009 to 2011, and forecast data are provided for each of the years 2011 through 2016. Historical, base year, and forecast data are provided for each market segment. Market shares are provided for each market segment for the 2011 base year.

All Kalorama Information reports advertise the single user price, which limits access to one user. We also feature department and global pricing for reports that will be utilized by more than one user at your company. Please ask your sales representative or select the correct license on our website.

For Kalorama's take on the healthcare news of the week, based on our analysis of healthcare markets, follow Kalorama Information's Key Point Blog at http://kaloramakeypoint.blogspot.com/

Additional Information

New York, December 5 , 2011-- Led by biologic therapies, the market for prescription arthritis treatments will exceed $20 billion in 2011, according to Kalorama Information. The healthcare market research publisher says that drugs that attack Tumor Necrosis Factor (TNF) led the market to 7.3% growth in revenues in 2010, and this type of growth is expected to continue, but not without challenges.

TNF is a type of cell death that leads to inflammation and is a main cause of arthritis pain. According to the report, products such as Remicade, Enbrel or Humira that can block TNF have been effective treatments and are leading in terms of revenue for the treatment of rheumatoid arthritis. Abbott's Humira leads the group of TNF products, but as the report's author suggests, the success of these products with rheumatologists and patients also means that it has become a competitive marketplace.

"Humira will likely become the world's biggest-selling drug by 2016, after the fall of Lipitor in 2011," said Melissa Elder, the report's author. "However, new products on the horizon and other factors may challenge this dominance over the next five years."

Entrants to this area include Bristol-Myers Squibb, with its recent introduction of Orencia, UCB with Cimzia and many others; so far the existing products have fended off those challenges. According to the report, some of the key factors that may challenge the dominance of treatments that attack TNF include new small molecule therapies that are attempting to vie for first-line utilization, the launch of biosimilars and physicians gaining comfort with IL-6 therapies; one or all of these could potentially derail the anti-TNF dominance.

The report notes that the prescription arthritis market is not without its challenges for all drug makers. Reimbursement for high-priced biologic medicines will be challenging over the next few years as payers seek to manage costs through purchasing arrangements and cost-sharing with their insured population, which could be a limiter to price growth, according to the report.

Table of Contents

TABLE OF CONTENTS CHAPTER ONE: EXECUTIVE SUMMARY

  • Introduction
  • Scope and Methodology
  • Product Market Summary
  • Issues and Trends Affecting Market
  • Competitor Analysis

CHAPTER TWO: INTRODUCTION

  • Overview
  • Local Joint Disorder Function
    • Etiology and Pathogenesis
    • Clinical Manifestations
  • Osteoarthritis
    • Etiology and Pathogenesis
    • Clinical Manifestations
    • Treatment
  • Infectious Arthritis
    • Etiology and Pathogenesis
    • Clinical Manifestations
    • Systemic Disorders of Joint Function
  • Rheumatoid Arthritis
    • Etiology and Pathogenesis
    • Clinical Manifestations
  • Ankylosing Spondylitis
    • Clinical Manifestations
  • Psoriatic Arthritis
    • Clinical Manifestations
  • Enteropathic Arthritis
    • Clinical Manifestations
  • Adult Onset Still Disease
    • Clinical Manifestations
  • Juvenile Rheumatoid Arthritis
    • Clinical Manifestations
  • Still Disease
  • Polyarticular Onset
  • World Demographics

CHAPTER THREE: WORLDWIDE NON-STEROIDAL ANTI-INFLAMMATORY DRUG MARKET

  • Product Description
  • Market Forecast and Growth
  • Markets by Geographical Region
    • United States
    • Europe
    • Japan
    • Rest of World
  • Competitive Landscape

CHAPTER FOUR: WORLDWIDE DISEASE-MODIFYING ANTI-RHEUMATIC DRUG TREATMENT MARKETS

  • Product Descriiption
    • Sulfasalazine (Azulfidine-Pfizer)
    • Gold Compounds
    • Penicillamine (Cuprimine-Merck)
    • Chloroquine (Aralen-Sanofi-Aventis)
    • Methotrexate (Trexall-Duramed; Rheumatrex-DAVA Pharmaceuticals)
    • Leflunomide (Arava-Sanofi-Aventis)
  • Market Forecast and Growth
  • Markets by Geographical Region
    • United States
    • Europe
    • Japan
    • Rest of World
  • Competitive Landscape

CHAPTER FIVE: WORLDWIDE BIOLOGICAL RESPONSE MODIFIERS AND IMMUNOSUPPRESSIVE DRUG MARKETS

  • Description
  • Tumor Necrosis Factor
  • Glucocorticoids
  • Azathioprine (Azasan-Salix)
  • Adalimumab (Humira-Abbott)
  • Anakinra (Kineret-Amgen)
  • Basiliximab (Simulect-Novartis)
  • Daclizumab (Zenapax-Roche)
  • Etanercept (Enbrel-Amgen)
  • Infliximab (Remicade-Janssen Biotech)
  • Rituximab (Rituxan-Biogen Idec)
  • Abatacept (Orencia-Bristol-Myers Squibb)
  • Market forecast and Growth
  • Markets by Geographical Region
    • United States
    • Europe
    • Japan
    • Rest of World
  • Competitive Landscape

CHAPTER SIX: WORLDWIDE ARTHRITIS TREATMENT MARKET SUMMARY AND COMPETITIVE ANALYSIS

  • Market Overview
  • Product Market Summary
  • Product Market Analysis by Geographical Region
  • 6 Worldwide Arthritis Treatment Products Competitive Analysis

CHAPTER SEVEN: ARTHRITIS RESEARCH AND DEVELOPMENT TREATMENTS

  • Overview
  • Duexis
  • Gel-One
  • ACZ
  • Apremilast
  • Fostamatinib
  • Lodotra
  • Stelara
  • Tofacitinib

CHAPTER EIGHT: ARTHRITIS TREATMENTS ISSUES AND TRENDS

  • Overview
  • US Economic Impact of Arthritis
  • World Economic Impact of Arthritis
  • Obesity and Arthritis
  • Trends in Insurance and Reimbursement
  • Threat to Anti-TNF Dominance
  • ADAM- Gene Discovery
  • New Pricing Structure in Germany

CHAPTER SEVEN: CONCLUSIONS

  • Conclusion One
  • Conclusion Two
  • Conclusion Three
  • Conclusion Four
  • Conclusion Five

CHAPTER EIGHT: COMPANY PROFILES

  • Introduction
  • Abbott Laboratories
  • Amgen, Inc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Galapagos NV
  • Genentech, Inc.
  • Horizon Pharma
  • Janssen Biotech, Inc
  • Novartis International AG
  • Pfizer, Inc.
  • Roche
  • Regeneron
  • UCB

LIST OF COMPANIES

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Summary Table: Total World Arthritis Treatment Revenue and Growth Rate by Drug Type 2011 ($millions)
  • Summary Figure:The World Prescription Arthritis Treatments Market Share Summary 2011

CHAPTER TWO: INTRODUCTION

  • Table 2-1: Total Global Population by Selected Geographical Region, 2000 - 2050
  • Table 2-2 World Prevalence of Rheumatoid Arthritis by Region
  • Figure 2-1:: World Prevalence of Rheumatoid Arthritis, Percent by Region

CHAPTER THREE: WORLDWIDE NON-STEROIDAL ANTI-INFLAMMATORY DRUG MARKET

  • Table 3-1: Select Marketed Non-steroidal Anti-inflammatory Drugs
  • Table 3-2 Market Size and Growth for NSAIDs in the Global Arthritis Treatment Market 2009-2016 ($millions)
  • Figure 3-1 Market Size and Growth for NSAIDs in the Global Arthritis Treatment Market 2009-2016 ($millions)
  • Table 3-3: The Worldwide Market for NSAIDs by Geographical Region (US, Europe, ROW) 2009-2016
  • Figure 3-2: The Worldwide Market for NSAIDs Products by Region (US, Europe, Japan, ROW), 2011
  • Figure 3-3: The Worldwide Market for NSAIDs Products by Region (US, Europe, Japan, ROW), 2016
  • Table 3-4: The Worldwide NSAIDs Product Market Share by Supplier 2011
  • Figure 3-4: The Worldwide NSAIDs Product Market Share by Supplier 2011

CHAPTER FOUR: WORLDWIDE DISEASE-MODIFYING ANTI-RHEUMATIC DRUG TREATMENT MARKETS

  • Table 4-1: Selected Prescription Disease Modifying Anti-Rheumatic Drugs
  • Table 4-2: Market Size and Growth for DMARDs in the Global Arthritis Treatment Market 2009-2016 ($millions)
  • Figure 4-1: Market Size and Growth for NSAIDs in the Global Arthritis Treatment Market 2009-2016 ($millions)

CHAPTER FIVE: WORLDWIDE BIOLOGICAL RESPONSE MODIFIERS AND IMMUNOSUPPRESSIVE DRUG MARKETS

  • Table 5-1: Selected Prescription Immunosuppressant and Other Biologic Drugs
  • Table 5-2 Market Size and Growth for BMRs and Immunosuppressants in the Global Arthritis Treatment Market 2009-2016 ($millions)
  • Figure 5-1 Market Size and Growth for BRMs and Immunosuppressants in the Global Arthritis Treatment Market 2009-2016 ($millions)
  • Table 5-3: The Worldwide Market for BRMs by Geographical Region (US, Europe, Japan, ROW) 2009-2016
  • Figure 5-2: The Worldwide Market for BRM Products by Region (US, Europe, Japan, ROW), 2011
  • Figure 5-3: The Worldwide Market for BRM Products by Region (US, Europe, Japan, ROW), 2016
  • Table 5-4: The World Biologic Response Modifiers Arthritis Treatment nd Market Share by Supplier 2011
  • Figure 5-4: The Worldwide BRMs and Immunosuppressives Product Market Share by Supplier 2011

CHAPTER SIX: WORLDWIDE ARTHRITIS TREATMENT MARKET SUMMARY AND COMPETITIVE ANALYSIS

  • Table 6-1: Total World Prescription Arthritis Treatment Revenue and Growth Rate by Drug Type 2011
  • Figure 6-1: The World Prescription Arthritis Treatments Market Share Summary 2011
  • Table 6-3: The World Market for Prescription Arthritis Treatments, by Geographic Region, 2011
  • Figure 6-2: The World Market for Prescription Rheumatoid Arthritis, by Geographic Region, 2011
Back to Top